0
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Solute carrier-related signature for assessing prognosis and immunity in patients with clear-cell renal cell carcinoma

      research-article
      1 , 2 , 3 , 2 , 1 , 2 ,
      Oncology Research
      Tech Science Press
      Clear cell renal cell carcinoma, Solute carrier, Bioinformatics, Metabolic reprogramming, Immune microenvironment

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background:

          Clear-cell renal cell carcinoma (ccRCC) is the most common malignant kidney cancer. However, the tumor microenvironment and crosstalk involved in metabolic reprogramming in ccRCC are not well-understood.

          Methods:

          We used The Cancer Genome Atlas to obtain ccRCC transcriptome data and clinical information. The E-MTAB-1980 cohort was used for external validation. The GENECARDS database contains the first 100 solute carrier (SLC)-related genes. The predictive value of SLC-related genes for ccRCC prognosis and treatment was assessed using univariate Cox regression analysis. An SLC-related predictive signature was developed through Lasso regression analysis and used to determine the risk profiles of patients with ccRCC. Patients in each cohort were separated into high- and low-risk groups based on their risk scores. The clinical importance of the signature was assessed through survival, immune microenvironment, drug sensitivity, and nomogram analyses using R software.

          Results:

          SLC25A23, SLC25A42, SLC5A1, SLC3A1, SLC25A37, SLC5A6, SLCO5A1, and SCP2 comprised the signatures of the eight SLC-related genes. Patients with ccRCC were separated into high- and low-risk groups based on the risk value in the training and validation cohorts; the high-risk group had a significantly worse prognosis ( p < 0.001). The risk score was an independent predictive indicator of ccRCC in the two cohorts according to univariate and multivariate Cox regression ( p < 0.05). Analysis of the immune microenvironment showed that immune cell infiltration and immune checkpoint gene expression differed between the two groups ( p < 0.05). Drug sensitivity analysis showed that compared to the low-risk group, the high-risk group was more sensitive to sunitinib, nilotinib, JNK-inhibitor-VIII, dasatinib, bosutinib, and bortezomib ( p < 0.001). Survival analysis and receiver operating characteristic curves were validated using the E-MTAB-1980 cohort.

          Conclusions:

          SLC-related genes have predictive relevance in ccRCC and play roles in the immunological milieu. Our results provide insight into metabolic reprogramming in ccRCC and identify promising treatment targets for ccRCC.

          Related collections

          Most cited references45

          • Record: found
          • Abstract: found
          • Article: not found

          Robust enumeration of cell subsets from tissue expression profiles

          We introduce CIBERSORT, a method for characterizing cell composition of complex tissues from their gene expression profiles. When applied to enumeration of hematopoietic subsets in RNA mixtures from fresh, frozen, and fixed tissues, including solid tumors, CIBERSORT outperformed other methods with respect to noise, unknown mixture content, and closely related cell types. CIBERSORT should enable large-scale analysis of RNA mixtures for cellular biomarkers and therapeutic targets (http://cibersort.stanford.edu).
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Systemic Therapy for Metastatic Renal-Cell Carcinoma

              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              SLC transporters as therapeutic targets: emerging opportunities.

              Solute carrier (SLC) transporters - a family of more than 300 membrane-bound proteins that facilitate the transport of a wide array of substrates across biological membranes - have important roles in physiological processes ranging from the cellular uptake of nutrients to the absorption of drugs and other xenobiotics. Several classes of marketed drugs target well-known SLC transporters, such as neurotransmitter transporters, and human genetic studies have provided powerful insight into the roles of more-recently characterized SLC transporters in both rare and common diseases, indicating a wealth of new therapeutic opportunities. This Review summarizes knowledge on the roles of SLC transporters in human disease, describes strategies to target such transporters, and highlights current and investigational drugs that modulate SLC transporters, as well as promising drug targets.
                Bookmark

                Author and article information

                Contributors
                Journal
                Oncol Res
                Oncol Res
                OR
                Oncology Research
                Tech Science Press (USA )
                0965-0407
                1555-3906
                2023
                10 April 2023
                : 31
                : 2
                : 181-192
                Affiliations
                [1 ]Department of Urology, The Second Affiliated Hospital of Nanjing Medical University , Nanjing, China
                [2 ]Department of Urology, The First Affiliated Hospital of Nanjing Medical University , Nanjing, China
                [3 ]Department of General Surgery, The Second Affiliated Hospital of Nanjing Medical University , Nanjing, China
                Author notes
                [* ]Address correspondence to: Min Gu, lancetgu@ 123456aliyun.com

                #These authors are co-first authors

                Article
                28051
                10.32604/or.2023.028051
                10208045
                37304236
                105ec677-f091-43f5-a2c9-a4c9ad6f6e16
                © 2023 BAO et al.

                This work is licensed under a Creative Commons Attribution 4.0 International License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

                History
                : 28 November 2022
                : 07 February 2023
                Funding
                Funded by: National Natural Science Foundation of China
                Award ID: 82170769
                Award ID: 81900684
                Award ID: 81870512
                Categories
                Article

                clear cell renal cell carcinoma,solute carrier,bioinformatics,metabolic reprogramming,immune microenvironment

                Comments

                Comment on this article